Open-label randomised trial of Tolvaptan versus fluid restriction in hospitalised patients with moderate-severe hyponatraemia
Grant number: 2005300 | Funding period: 2021 - 2024
Low blood sodium level, known as hyponatraemia, is the most common electrolyte problem. It occurs in 15% of hospital patients, and can cause confusion, seizure and fatal brain swelling. Standard treatment for hyponatraemia is limiting oral fluid, but this is slow and not always effective. The drug tolvaptan works in mild hyponatraemia, but hasn't been formally tested in severe cases. We will compare benefits and risks of tolvaptan versus fluid restriction in patients with severe hyponatremia.
Related publications (1)
Tolvaptan versus fluid restriction in acutely hospitalised patients with moderate-profound hyponatraemia (TVFR-HypoNa): design and implementation of an open-label randomised trial
Annabelle M Warren, Mathis Grossmann, Rudolf Hoermann, Jeffrey D Zajac, Nicholas Russell
BACKGROUND: Current hyponatraemia guidelines are divided on the use of tolvaptan in hospitalised patients with moderate to severe ..